Increasing awareness among the general population and the ongoing research activities by manufacturers for the PH1 type to boost the demand
Increasing awareness among the general population and the ongoing research activities by manufacturers for the PH1 type to boost the demand
Fact.MR, Dubai: The latest report on global primary hyperoxaluria treatment by Fact.MR projects a moderate growth in the upcoming years. Advancement of technology in the field of genetic engineering and surge in R&D activities for drug development treatment is boosting the demand for primary hyperoxaluria treatment market.
According to the study, healthcare professional are extensively focusing in decreasing the impact caused by the disease by conducting R&D initiatives with the collaboration between hospitals and manufacturers. PH1 (primary hyperoxaluria type 1) is the severest form of the disease accounting for 80% of the cases, that leads to kidney failure. Therefore, the manufacturers are increasing their research for the treatment of PH1, bolstering the demand.
Furthermore, according to the report of U.S national organization of rare disease with the prompt treatment and diagnose of PH1 the chronic kidney disease and organ failure such as heart, eyes and bones can be treated. The condition is very rare with an estimated prevalence of 0.05 people in 10,000. As a consequence of, there has been limited number of clinical data to carry an extensive research for the treatment of PH1. Hence, posing a challenge to the market growth.
“Increasing collaboration between hospitals and research bodies for fast track drug approvals and clinical trials is supporting primary hyperoxaluria treatment market growth,” says the Fact.MR analyst.
Request a report sample to gain comprehensive insights at https://www.factmr.com/connectus/sample?flag=S&rep_id=5257
Key Takeaways
- Primary hyperoxaluria treatment type 1 is expected to dominate the market
- Pyridoxine drug expected to be the most lucrative segment through 2030
- Bases on the route of administration, oral route to be the most widely used method in primary hyperoxaluria treatment market
- Hospital pharmacies expected to be the largest distribution channel followed by retail pharmacies
- Online pharmacies expected to emerge as the potential segment through 2021
- Growing government support and regulatory authorities initiatives to propel growth in US
- Increasing R&D activities by private players due to the rarity of the disease to create lucrative growth opportunities for Chinese market
Prominent Drivers
- Heightened investment and increased genetic testing to drive the market demand
- Advancement of technology in the field of genetic engineering to boost the primary hyperoxaluria treatment market
Key Restraints
- Rarity of disease among the population to restrict the growth of the market
Discover more about the Primary hyperoxaluria treatment market with figures, data tables and the table of contents. You will also find detailed market segmentation on https://www.factmr.com/report/5257/primary-hyperoxaluria-treatment-market
Competitive Landscape
Alnylam Pharmaceuticals Inc., Tecoland Corporation, Zhejiang Tianxin Pharmaceutical Co., Takeda Pharmaceuticals, Wuxi Further Pharmaceutical Co. Ltd., and Genentech are some of the key players profiled by Fact.MR. Advanced drug and clinical trials done by research institutes is creating growth opportunities for the key players.
For instance, in November 2020, Alnylam received approval for OXLUMO (lumasiran) in the European Union for the treatment of primary hyperoxaluria type 1 for all age groups.
More Insights on the Primary Hyperoxaluria Treatment Market
In its latest market research study, Fact.MR gives a detailed segmentation on the global primary hyperoxaluria treatment. In order to understand the global market potential and scope, the market is segmented on the basis of disease type (type 1, type 2 and type 3), drug (pyridoxine, potassium citrate, thiazides, and orthophosphates), route of administration (oral, intravenous and others), distribution channel (hospital pharmacies, retail pharmacies, drug stores, and online), and regions (North America, Latin America, South Asia, East Asia, Oceania and Middle East & Africa)
Explore Fact.MR’s Coverage on the Healthcare Domain
Peptide Based Metabolic Disorders Therapeutics Market: Fact.MR’s recent study on the global peptide based metabolic disorders therapeutics offers 10-year forecast. The study analyzes crucial trends that are currently determining market growth. This report explicates on vital dynamics, such as the drivers, restraints, challenges and opportunities for key market players along with key stakeholders and emerging players.
Genetic Disorder Therapeutics Market: Fact.MR’s exhaustive analysis on global genetic disorder therapeutics market offers value chain analysis, business execution, and supply chain analysis across regional markets has been covered in the report. A list of prominent companies operating in the market along with their product portfolios enhances the reliability of this comprehensive research study.
Rare Neurological Disease Treatment Market: Fact.MR has published a detailed research study on the global market for rare neurological disease treatment. The study provides an in-depth analysis on the key market dynamics, including drivers, trends, opportunities restraints, and detailed information about the rare neurological disease treatment market structure.
About Fact.MR
Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner.
Contact:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E: sales@factmr.com
Follow Us: LinkedIn | Twitter
Market Intelligence Services: Marketngage.com
Source: Fact.MR